RayzeBio multiple targets targeted radiopharmaceutical

RayzeBio's multiple targets targeted radiopharmaceutical, also known as Pre-clinical candidate 2, is an early-stage therapeutic program developed by RayzeBio, a subsidiary of Bristol Myers Squibb. This program is part of a pipeline focused on targeted radiopharmaceutical therapeutics (RPTs), which combine a targeting moiety (such as a peptide or small molecule) with a therapeutic radioisotope to deliver ionizing radiation directly to cancer cells. While the specific biological targets and primary disease indications for this program have not been publicly disclosed, it represents an expansion of RayzeBio's platform beyond single-target agents like RYZ101. The program likely utilizes alpha-emitting isotopes, such as Actinium-225, to induce double-stranded DNA breaks in tumor cells expressing the relevant targets.

Other names

RAYNZ-Multiple targets-targeted radiopharmaceutical